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The evaluation of short-term prognosis after PCI of unstable angina pectoris
patients for triple antiplatelet therapy
Han Gaojie, Li Yongjun
The Second Hospital of He Bei Medical University
Objectives: Investigate the triple antiplatelet therapy on the evalua- tion of short-term
prognosis of unstable angina pectoris patients after PCI, in order to supply a clinical
evidence for patients who were treated by PCI with preoperative and postoperative
antiplatelet choices.
Methods: Selective PCI patients with UAP 302 cases (male 172 cases, females 130
cases) in our hospital were randomly divided into control group which was double
antiplatelet treatment therapy group(aspirin and clopidogrel, 151 cases ) and triple
antiplatelet therapy group (aspirin, clopidogrel and cilostazol,151 cases). The day
before PCI the dual antiplatelet therapy group was given aspirin and clopidogrel
loading capacity 300 mg, after PCI aspirin was 100 mg once a day and clopidogrel 75
mg. While the day before PCI the triple antiplatelet therapy groupe was given aspirin
and clopidogrel load capacity 300 mg, load capacity for cilostazol was 200 mg, after
PCI patients in TT were given aspirin 100 mg once a day, clopidogrel 75 mg once a
day and cilostazol 100 mg twice a day. Observing in patients with high sensitivity C
reactive protein (hs-CRP), cardiac markers, adverse cardiovascular and cerebrovas-
cular events (MACCE) and bleeding events.
Results: (1) There were no obvious differences in clinical characteristics[age, sex,
hypertension, diabetes, smoking history, proton pump inhibitors(PPI),the average
number of vascular lesions,the average number of stent implantation between the
double groups](P> 0.05). (2) Using hs-CRP as a sign of inﬂammatory injury, there
was no striking difference between the two groups before PCI 24h(4.670.56 vs
4.630.35, P¼0.633).The follow-up 24h hs-CRP there was a clear difference between
the conventional treatment group and the TT group(7.690.75 vs 6.030.63,
P<0.001). (3) Detect CK-MB and cTnI after PCI 16h, the values were signiﬁcantly
higher than the preoperative ones(double antiplatelet group CK-MB:16.803.26
vs 11.302.38;cTnI:0.180.02 vs 0.060.02;triple antiplatelet group CK-
MB:14.302.78 vs 10.903.02;cTnI:0.17 0.04 vs 0.060.02). But after 16h triple
antiplatelet group compared with dual antiplatelet group CK-MB and cTnI were
signiﬁcantly decreased (CK-MB: 16.804.3.26 vs 14.302.78, P<0.001; cTnI:
0.180.02 vs 0.170.04, P¼0.017). (4) After PCI 30 days the two groups had no
serious bleeding to stop anti- platelet therapy in patients. In the dual antiplatelet
therapy group there were 6 cases of a little bleeding and 9 cases of minor blee-
ding,while 6 cases of a little bleeding and 15 cases of minor bleeding in the triple
antiplatelet group.There was no obvious difference between the dule groups(10% vs
14%, P¼0.538). (5) Within PCI 30 days,there were 3 cases of cardiac death,9 cases
of myocardial infarction,6 patients with revascularization and 6 patients with cerebral
stroke in the dual antiplatelet therapy group.While in the triple antiplatelet group,-
there were 3 cases of myocardial infarction and 3 patients with revascularization.The
incidence of MACCE in the triple anti- platelet group was lower than dual anti-
platelet therapy group (16% vs 4%, P¼0.046).
Conclusions: Compared with dual antiplatelet therapy, preoperative PCI triple anti-
platelet therapy based on the load capacity of cilostazol can reduce postoperative
inﬂammatory reaction and the incidence of MACCE after PCI. At the same time PCI
does not increase the incidence of postoperative hemo- rrhage.
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Evidence-based Comparative Safety of Atorvastatin 10mg versus 80mg in
Chinese Atherosclerosis Patients
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Objectives: To compare the safety proﬁle of atorvastatin 80mg with that of ator-
vastatin 10mg in Chinese atherosclerosis patients based on systematic review.
Methods: Literatures were retrieved from PubMed, EMBASE, CENTRAL,
CBMDisc, CMCI, CNKI, VIP and Wanfang database (March 2013). The quality
assessment, data extraction and veriﬁcation of collected literatures were conducted by
two reviewers independently. Review Manager 5.2.1 and Indirect Treatment Com-
parisons (ITC) software were applied to compute direct and indirect effects of adverse
reactions. Then the results were described by Odds ratios (OR) and 95% conﬁdence
intervals (95% CI) in each comparison group.
Results: In total 19 qualiﬁed literatures with 1761 atherosclerosis patients were
included. The maximum treatment period was 5 years. Adverse reactions such as
drug-induced abnormal liver function, myalgia, creatine phosphokinase and gastro-
intestinal reactions were investigated in 19, 12, 6 and 6 studies respectively. The
numbers of direct comparisons in drug-induced abnormal liver function of 10mg vs
80mg, 10mg vs 20mg, 20mg vs 80mg, 10mg vs 40mg, and 40mg vs 80mg were 2, 6,
4, 7, and 1, respectively. The OR of direct effect of drug-induced abnormal liver
function in 10mg vs 80mg was 0.43 (95% CI 0.06-2.97). Similarly, the OR of direct
effect in 10mg vs 20mg, 20mg vs 80mg, and 10mg vs 40mg were 0.54(95% CI 0.23-
1.26), 0.60(95% CI 0.15-2.41), and 0.32(95% CI 0.10-1.01), respectively. No drug-
induced abnormal liver function was observed in direct comparisons of 40mg vs
80mg. To compare the indirect effects, setting 20mg as a common comparator in ITC,
the OR of indirect effect in 10mg vs 80mg group was 0.324 (95% CI 0.064-1.651).
Changing the common comparator from 20mg to 40mg, the OR of indirect effect was
dropped to 0.298 (95% CI 0.005-17.263). No drug-induced myalgia was described inC204 JACC Vol 64/16/Suppl C j October 16–1direct comparisons of 10mg vs 80mg, and setting 20mg as a common comparator, the
OR of indirect effect of drug-induced myalgia in 10mg vs 80mg was 0.105 (95% CI
0.006-1.753).
Conclusions: Our results did not ﬁnd signiﬁcant differences between 10mg atorvas-
tatin group and 80mg atorvastatin group in Chinese atherosclerosis patients for
drug-induced abnormal liver function and myalgia based on the results of direct and
indirect comparison. Similarly, no signiﬁcant difference was found between 10mg
and 40mg in drug-induced abnormal liver function based on the results of direct
comparison.
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Effects of heart rate control with ivabradine plus beta-blocker on exercise
tolerance in patients after Q-wave myocardial infarction with early left
ventricular systolic dysfunction
Xu Yao, Bezrodnyi Andrii
Bogomolets National Medical University, Kyiv, Ukraine
Objectives: To investigate the effects of heart rate (HR) control with combination of
ivabradine and beta-blocker versus uptitration of beta-blocker on exercise tolerance in
patients after Q-wave myocardial infarction (MI) with early left ventricular ejection
fraction (LVEF) <45% at 6-month follow-up.
Methods: In single-blind parallel-group study 28 patients with a ﬁrst Q-wave MI
and early LVEF 30-45%, sinus rhythm > 80 bpm, Killip class I-II, after reperfusion
therapy by percutaneous coronary intervention in 12 patients (42.9%) and throm-
bolysis in 16 (57.1%) were randomized into 2 groups. As part of standard therapy,
all patients at the time of hospital admission received metoprolol tartrate 12.5 mg
bid. Apart from metoprolol tartrate (up-titrated to 25 mg bid at day 5, average daily
dose 55.31.7 mg), at day 5 patients in group 1 (n¼16) received ivabradine 2.5 mg
bid (up-titrated to 7.5 mg bid, average daily dose 11.31.5 mg). In group 2 (n¼12)
metoprolol tartrate was up-titrated to 75 mg bid (average daily dose 105.45.2
mg). The two groups were similar for clinical characteristics. No difference was
evidenced in initial resting HR and LVEF between two groups at entry (87.31.6
vs 86.71.5 bpm, 38.51.4 vs 38.91.5%, respectively, all P>0.05). Besides
LVEF at admission, day 28 and after 6 months, symptom-limited treadmill test
(Bruce protocol) to conduct stress tests at the trough of drug activity (12 h after last
intake of ivabradine and metoprolol tartrate) was performed at day 28 and after
6 months.
Results: Resting HR decreased similarly in both groups (at day 28 - 62.51.5 vs
63.71.4 bpm, after 6 months - 61.31.5 vs 62.81.6 bpm, all P>0.05). Group 1
showed a signiﬁcant increase in LVEF (at day 28 - increased to 46.31.5%, after
6 months - up to 49.11.7%, all P<0.01). In group 2 LVEF didn’t change signiﬁ-
cantly (at day 28 - 42.11.5%, after 6 months - 43.21.6%, all P>0.05). The dif-
ference in LVEF at day 28 after initial treatment between the 2 groups was signiﬁcant
(P<0.01). After 6 months, threshold load capacity, exercise duration and chronotropic
reserve signiﬁcantly improved in both groups in comparison to basal levels (in group
1 - 6.30.4 vs 5.00.3 MET, 257.312.6 vs 209.412.4 s, 54.22.8 vs 42.32.5
bpm, all P<0.01; in group 2 - 5.20.3 vs 4.10.3 MET, 211.312.5 vs
168.212.2 s, 43.82.9 vs 34.52.8 bpm, respectively, all P<0.05). However, in
group 1 compared to group 2 higher threshold load capacity, exercise duration and
chronotropic reserve (all P<0.01) were attained in spite of higher HR at peak exercise
(at day 28 - 107.32.6 vs 98.62,5 bpm, after 6 months - 129.52.7 vs 106.82.6
bpm, respectively, all P<0.01).
Conclusions: In patients after Q-wave MI with early LVEF < 45%, ivabradine in
combination with low dose metoprolol tartrate, besides improvement in left ventric-
ular systolic function, increased exercise tolerance at 6-month follow-up.
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The systematic review on Wendan decoction’s clinical efﬁcacy in the treatment of
Arrhythmia
Ma Nana, Li Ping
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Objectives: Although the research about WenDan decoction treatment of arrhythmia a
lot, it is lack of rigorous, system evaluation, also cannot form the objective evidence.
Therefore this research will evaluate the clinical efﬁcacy and safety of Wendan
decoction in the treatment of arrhythmia, provide new ideas and the new method for
clinical treatment of arrhythmia.
Methods: According to the method of Cochrane systematic review, Literatures from
WANFANG database, VIP database, the full text of the CNKI database, CBM
database and Medline database regarding randomized controlled trials and half a
randomized controlled trials of Wendandecoction in the treatment of arrhythmia were
reviewed. As all searches end in 2014. Related literatures were selected and analyzed
according to the standards. The method ologicalquality of the trials was assessed by
quality evaluation standard which was recommendated by the Cochrane systematic
review manual 5.2 and evaluation was performed with software RevMan5.2.And
heterogeneity test, sensitivity and bias analysis was carried on.
Results: Eleven randomized controlled trials meting the inclusion criteria were
selected and reviewed. All selected trials are in Chinese. A total of 990 patients, the
treatment group of 534 people, the control group of 456 people. Only 2 trial is in high
quality, the others are not. Meta-analysis results shown: in the comparison with
control group ,the clinical total effective rate of the Wendan decoction in the treatment9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
